Valacyclovir — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Herpes Simplex & Zoster

• Acyclovir
• Acyclovir 400/800 mg tabs

Other medications in Infections

• Valganciclovir
• Vancomycin
• Velpatasvir
• Voriconazole
• Zanamivir
• Zidovudine
• Abacavir
• Adefovir

What Valacyclovir is approved for (FDA label)

Valacyclovir tablets are a deoxynucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) Cold Sores (Herpes Labialis) Genital Herpes Treatment in immunocompetent patients (initial or recurrent episode) Suppression in immunocompetent or HIV-1-infected patients Reduction of transmission Herpes Zoster Pediatric Patients ( 1.2 ) Cold Sores (Herpes Labialis) Chickenpox Limitations of Use ( 1.3 ) The efficacy and safety of valacyclovir tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-1-infected patients. 1.1 Adult Patients Cold Sores (Herpes Labialis) Valacyclovir tablets are indicated for treatment of cold sores (herpes labialis).

Source: Read the full FDA label on DailyMed. Label effective date: September 5, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Valacyclovir (FDA label)

Tablets: Valacyclovir Tablets, USP 500-mg: Blue, film-coated, capsule-shaped tablets, debossed with "Y131" on one side contains 556.2 mg of valacyclovir hydrochloride equivalent to 500 mg of the free base. Valacyclovir Tablets, USP 1-gram: Blue, film-coated, capsule-shaped tablets, with a partial scorebar on both sides, debossed with "Y132" on one side contains 1.112 grams of valacyclovir hydrochloride equivalent to 1 gram of the free base. Tablets: 500 mg (unscored), 1 gram (partially scored) ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 14e479b1-8afd-4912-8f93-59b60a0868bc. SPL document ID: 5ab75e6e-01f5-5306-e063-6294a90a70a5. Label effective date: September 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Valacyclovir (FDA label)

The following serious adverse reactions are discussed in greater detail in other sections of the labeling: Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome [see Warnings and Precautions (5.1) ]. Acute Renal Failure [see Warnings and Precautions (5.2) ]. Central Nervous System Effects [see Warnings and Precautions (5.3) ]. Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.4) ]. The most common adverse reactions reported in at least 1 indication by greater than 10% of adult subjects treated with valacyclovir tablets and observed more frequently with valacyclovir tablets compared with placebo are headache, nausea, and abdominal pain. The only adverse reaction reported in greater than 10% of pediatric subjects aged less than 18 years was headache.

Source: FDA prescribing information (DailyMed). Set ID: 14e479b1-8afd-4912-8f93-59b60a0868bc. SPL document ID: 5ab75e6e-01f5-5306-e063-6294a90a70a5. Label effective date: September 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Valacyclovir (FDA label)

Valacyclovir tablets are contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction [e.g., anaphylaxis, severe cutaneous adverse reactions (SCARs)] to valacyclovir, acyclovir, or any component of the formulation [see Warnings and Precautions (5.4) , Adverse Reactions (6.3) ] . Hypersensitivity to valacyclovir (e.g., anaphylaxis), acyclovir, or any component of the formulation. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 14e479b1-8afd-4912-8f93-59b60a0868bc. SPL document ID: 5ab75e6e-01f5-5306-e063-6294a90a70a5. Label effective date: September 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Valacyclovir (FDA label)

Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): Has occurred in patients with advanced HIV-1 disease and in allogenic bone marrow transplant and renal transplant patients receiving 8 grams per day of valacyclovir tablets in clinical trials. Discontinue treatment if clinical symptoms and laboratory findings consistent with TTP/HUS occur. ( 5.1 ) Acute renal failure: May occur in elderly patients (with or without reduced renal function), patients with underlying renal disease who receive higher-than-recommended doses of valacyclovir tablets for their level of renal function, patients who receive concomitant nephrotoxic drugs, or inadequately hydrated patients.

Source: FDA prescribing information (DailyMed). Set ID: 14e479b1-8afd-4912-8f93-59b60a0868bc. SPL document ID: 5ab75e6e-01f5-5306-e063-6294a90a70a5. Label effective date: September 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Valacyclovir (FDA label)

No clinically significant drug-drug or drug-food interactions with valacyclovir tablets are known [see Clinical Pharmacology (12.3) ].

Source: FDA prescribing information (DailyMed). Set ID: 14e479b1-8afd-4912-8f93-59b60a0868bc. SPL document ID: 5ab75e6e-01f5-5306-e063-6294a90a70a5. Label effective date: September 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.